A neuroendocrine tumor (NET) is a slow-growing type of cancer that begins in your hormone-producing cells. It is rare, but doctors diagnose more cases each year. An estimated 170,000 Americans ...

PRRT retreatment may be well tolerated and confer a survival benefit in patients with well-differentiated, metastatic neuroendocrine tumors, a study suggests.

Neuroendocrine tumors (NETs) are cancers that begin in specialized cells called neuroendocrine cells. These tumors are rare and can occur anywhere in the body. Most neuroendocrine tumors occur in the ...

PNETs are classified as functional or non-functional, influencing symptoms and treatment strategies. Tumor grade impacts prognosis and treatment plans. Diagnosis involves imaging, blood tests, and ...

A statistically significant and clinically meaningful improvement in PFS was observed with cabozantinib, compared with placebo, in the phase 3 CABINET study. The Food and Drug Administration (FDA) has ...

Cabometyx is approved for treating well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors in patients 12 years and older. The phase 3 CABINET trial showed improved progression-free ...

Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo. The Food and Drug Administration (FDA) has approved Cabometyx ® (cabozantinib) for ...

Adding the somatostatin analog lanreotide to the mTOR inhibitor everolimus significantly prolonged progression-free survival in patients with unresectable or recurrent gastroenteropancreatic ...

Exelixis, Inc. EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib). The regulatory body approved Cabometyx for the treatment of adult and pediatric ...

T1 Tumor limited to the pancreas and size <2 cm T2 Tumor limited to the pancreas and size 2–4 cm T3 Tumor limited to the pancreas and size >4 cm or invading duodenum or bile duct T4 Tumor invading ...